Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-26T06:56:21.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Serratia Bacteremia in a Large University Hospital: Trends in Antibiotic Resistance During 10 Years and Implications for Antibiotic Use

Published online by Cambridge University Press:  02 January 2015

Sang-Ho Choi ,
Yang Soo Kim ,
Jin-Won Chung ,
Tae Hyong Kim ,
Eun Ju Choo ,
Mi-Na Kim ,
Baek-Nam Kim ,
Nam Joong Kim ,
Jun Hee Woo  and
Jiso Ryu
Sang-Ho Choi
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Yang Soo Kim
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Jin-Won Chung
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Tae Hyong Kim
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Eun Ju Choo
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Mi-Na Kim
Affiliation:
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Baek-Nam Kim
Affiliation:
Division of Infectious Diseases, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea
Nam Joong Kim
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Jun Hee Woo*
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Jiso Ryu
Affiliation:
Division of Infectious Disease, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
*
Division of Infectious Diseases, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, 138-736, Seoul, South Korea
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To identify antibiotic resistance trends and risk factors for resistance of Serratia species to third-generation cephalosporins.

Design:

Retrospective survey of medical records.

Setting:

A 2,200-bed, tertiary-care hospital.

Patients:

One hundred twenty-two patients with Serratia bacteremia between January 1991 and June 2001.

Methods:

Infectious disease physicians collected data from medical records regarding patient demographics, underlying disease or condition, portal of entry, microorganism, antibiogram, complications, antibiotics received, and outcome.

Results:

Among 122 Serratia isolates, 117 (95.9%) were Serratia marcescens and 110 (90.2%) were of nosocomial origin. During the study period, the 122 isolates showed a high rate of resistance to third-generation cephalosporins (45.9%) and extended-spectrum penicillins (56.6%). The resistance rate to ciprofloxacin was 32.0%. The resistance rate to third-generation cephalosporins increased from 31.7% for 1991 to 1995 to 54.9% for 1996 to 1998 and 50.0% for 1999 to 2001. In the multivariate analysis, prior use of a second-generation cephalosporin (adjusted odds ratio [OR], 5.90; 95% confidence interval [CI95], 1.41 to 24.6; P = .015) or a third-generation cephalosporin (OR, 3.26; CI95, 1.20 to 8.87; P = .020) was a strong independent risk factor for resistance to third-generation cephalosporins. The overall case-fatality rate was 25.4% (Serratia bacteremia-related case-fatality rate, 13.1%).

Conclusion:

Prior use of a second- or third-generation cephalosporin was the most important risk factor for bacteremia with Serratia resistant to third-generation cephalosporins, suggesting the need for antibiotic control. The potential role of patient-to-patient spread could not be fully evaluated in this retrospective study.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 23 , Issue 12 , December 2002 , pp. 740 - 747
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Gatell, JM, Trilla, A, Latorre, X, et al. Nosocomial bacteremia in a large Spanish teaching hospital: analysis of factors influencing prognosis. Rev Infect Dis 1988;10:203–210.Google Scholar
2.Pfaller, MA, Jones, RN, Marshall, SAet al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28:211–219.Google Scholar
3.Edmond, MB, Wallace, SE, McClish, DK, Pfaller, MA, Jones, RN, Wenzel, RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239–244.Google Scholar
4.Richards, NM, Levitsky, S. Outbreaks of Serratia marcescens infections in a cardiothoracic surgical intensive care unit. Ann Thorac Surg 1975;19:503–513.Google Scholar
5.Geiseler, PJ, Harris, B, Andersen, BR. Nosocomial outbreak of nitrate-negative Serratia marcescens infections. J Clin Microbiol 1982;15:728–730.Google Scholar
6.Duggan, TG, Leng, RA, Hancock, BM, Cursons, RT. Serratia marcescens in a newborn unit: microbiological features. Pathology 1984;16:189–191.Google Scholar
7.Fry, DE, Fry, RV, Shlaes, DM. Serratial bacteremia in the surgical patient. Am Surg 1987;53:438–441.Google Scholar
8.Villarino, ME, Jarvis, WR, O'Hara, C, Bresnahan, J, Clark, N. Epidemic of Serratia marcescens bacteremia in a cardiac intensive care unit. J Clin Microbiol 1989;27:2433–2436.Google Scholar
9.Sokalski, SJ, Jewell, MA, Asmus-Shillington, , , AC, Mulcahy, J, Segreti, J. An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Arch Intern Med 1992;152:841–844.Google Scholar
10.van Ogtrop, ML, van Zoeren-Grobben, D, Verbakel-Salomons, EM, van Boven, CP. Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature. J Hosp Infect 1997;36:95–103.Google Scholar
11.Harnett, SJ, Allen, KD, Macmillan, RR. Critical care unit outbreak of Serratia liquefaciens from contaminated pressure monitoring equipment. J Hosp Infect 2001;47:301–307.Google Scholar
12.Grohskopf, LA, Roth, VR, Feikin, DRet al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med 2001;344:1491–1497.CrossRefGoogle Scholar
13.Yu, VL. Serratia marcescens: historical perspective and clinical review. N Engl J Med 1979;300:887–893.Google Scholar
14.Eisenstein, BI, Zaleznik, DE. Enterobacteriaceae. In: Mandell, GL, Douglas, RG, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone; 2000:2297–2310.Google Scholar
15.Livermore, DM. Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987;6:439–445.Google Scholar
16.Sanders, CC, Sanders, WE Jr. β-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824–839.CrossRefGoogle ScholarPubMed
17.Bennett, PM, Chopra, I. Molecular basis of β-lactamase induction in bacteria. Antimicrob Agents Chemother 1993;37:153–158.Google Scholar
18.Dworzack, DL, Pugsley, MP, Sanders, CC, Horowitz, EA. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur J Clin Microbiol 1987;6:456–459.Google Scholar
19.Dodson, WH. Serratia marcescens septicemia. Arch Intern Med 1968,121: 145–150.Google Scholar
20.Wilfert, JN, Barrett, FF, Kass, EH. Bacteremia due to Serratia marcescens. N Engl J Med 1968;279:286–289.Google Scholar
21.Henjyoji, EY, Whitson, TC, Ohashi, DK, Allen, BD. Bacteremia due to Serratia marcescens. J Trauma 1971;11:417–421.Google Scholar
22.Crowder, JG, Gilkey, GH, White, AC. Serratia marcescens bacteremia: clinical observations and studies of precipitin reactions. Arch Intern Med 1971;128:247–253.Google Scholar
23.Bouza, E, Garcia de la Torre, M, Erice, A, Cercenado, E, Loza, E, Rodriguez-Creixems, M. Serratia bacteremia. Diagn Microbiol Infect Dis 1987;7:237–247.Google Scholar
24.Sanchez Ruano, JJ, Garcia Díaz, JD, Alonso Navas, F. Serratia marcescens bacteremia: a report of 83 cases [in Spanish]. Medica Clinica 1988; 90:479–483.Google Scholar
25.Saito, H, Elting, L, Bodey, GP, Berkey, R. Serratia bacteremia: review of 118 cases. Rev Infect Dis 1989;11:912–920.CrossRefGoogle ScholarPubMed
26.Watanakunakorn, C. Serratia bacteremia: a review of 44 episodes. Scand J Infect Dis 1989;21:477–483.Google Scholar
27.Wong, WW, Wang, LS, Cheng, DL, et al. Serratia marcescens bacteremia. J Formos Med Assoc 1991;90:88–93.Google Scholar
28.Haddy, RI, Mann, BL, Nadkarni, DD, et al. Nosocomial infection in the community hospital: severe infection due to Serratia species. J Fam Pract 1996;42:273–277.Google Scholar
29.Yu, WL, Lin, CW, Wang, DY. Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates. J Microbiol Immunol Infect 1998;31:171–179.Google Scholar
30.McCabe, WR, Jackson, GG. Gram-negative bacteremia: II. Clinical, laboratory, and therapeutic observations. Arch Intern Med 1962;110:856–864.Google Scholar
31.Chow, JW, Fine, MJ, Shlaes, DM, et al. Enterobacterbacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585–590.Google Scholar
32.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.Google Scholar
33.Jones, RN. Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998;31:461–466.Google Scholar
34.D'Agata, E, Venkataraman, L, DeGirolami, R, Weigel, L, Samore, M, Tenover, E. The molecular and clinical epidemiology of Enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. J Infect 1998;36:279–285.Google Scholar
35.De Champs, C, Rouby, D, Guelon, D, et al. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase.J Hosp Infect 1991;18:5–13.Google Scholar
36.Jacoby, GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactamse. Incet Dis Clin North Am 1997;11:875–887.CrossRefGoogle Scholar
37.Kaye, KS, Fraimow, HS, Abrutyn, E. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2000;14:293–319.Google Scholar
38.Meyer, KS, Urban, C, Eagan, JA, Berger, BJ, Rahal, JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353–358.Google Scholar
39.Pena, C, Pujol, M, Ardanuy, C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998;42:53–58.Google Scholar
40.Schiappa, DA, Hayden, MK, Matushek, MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996;174: 529–536.Google Scholar
41.Wiener, J, Quinn, JP, Bradford, PAet al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517–523.Google Scholar
42.Livermore, DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557–584.Google Scholar
43.Pitout, JD, Sanders, CC, Sanders, WE Jr. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51–59.Google Scholar
44.Jacobson, KL, Cohen, SH, Inciardi, JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin Infect Dis 1995;21:1107–1113.Google Scholar
45.Sahm, DF, Storch, G. Amp C β-lactamases. Pediatr Infect Dis J 1998; 17:421–422.Google Scholar
46.Sanders, WE Jr, Sanders, CC. Inducible β-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988;10:830–838.Google Scholar
47.Livermore, DM. Carbapenemases. J Antimicrob Chemother 1992;29:609–613.CrossRefGoogle ScholarPubMed
48.Naas, T, Vandel, L, Sougakoff, W, Livermore, DM, Nordmann, P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother 1994;38:1262–1270.Google Scholar
49.Palomar, J, Puig, M, Montilla, R, Loren, JG, Vinas, M. Lipopolysaccharide recovery restores susceptibility levels towards β-lactamase in Serratia marcescens. Microbios 1995;82:21–26.Google Scholar
50.Cunha, BA. Antibiotic resistance. Med Clin North Am 2000;84:1407–1429.Google Scholar
51.Friedrich, LV, White, RL, Bosso, JA. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin Infed Dis 1999;28:1017–1024.Google Scholar
52.Kaye, KS, Cosgrove, S, Harris, A, Eliopoulos, GM, Carmeli, Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobader spp. Antimicrob Agents Chemother 2001;45:2628–2630.Google Scholar